Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
Neurology
|
November 19, 2024
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD
Pakeeran Siriratnam, Saif Huda, Anneke Van Der Walt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
Pakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years
Jodie I Roberts, Sifat Sharmin, Dana Horakova, et al.
Acta Neurologica Belgica
|
June 12, 2014
Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program
Vincent van Pesch, Emmanuel Bartholomé, Véronique Bissay, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 7, 2025
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)
Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, et al.
BMJ Open
|
September 11, 2019
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration
Barbara Willekens, Silvia Presas-Rodríguez, M J Mansilla, et al.
Therapeutic Advances in Neurological Disorders
|
November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study
David Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Izanne Roos, Sifat Sharmin, Charles Malpas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
April 3, 2024
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study
Cathérine Dekeyser, Matthias Hautekeete, Melissa Cambron, et al.
Brain : a Journal of Neurology
|
August 4, 2025
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis
Tomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
Neurology
|
November 19, 2024
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD
Pakeeran Siriratnam, Saif Huda, Anneke Van Der Walt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
Pakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years
Jodie I Roberts, Sifat Sharmin, Dana Horakova, et al.
Acta Neurologica Belgica
|
June 12, 2014
Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program
Vincent van Pesch, Emmanuel Bartholomé, Véronique Bissay, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 7, 2025
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)
Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, et al.
BMJ Open
|
September 11, 2019
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration
Barbara Willekens, Silvia Presas-Rodríguez, M J Mansilla, et al.
Therapeutic Advances in Neurological Disorders
|
November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study
David Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Izanne Roos, Sifat Sharmin, Charles Malpas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
April 3, 2024
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study
Cathérine Dekeyser, Matthias Hautekeete, Melissa Cambron, et al.
Brain : a Journal of Neurology
|
August 4, 2025
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis
Tomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Page
of 8